PTC Therapeutics director resigns, becomes consultant
PTC Therapeutics reports that board member Alethia Young resigned from its board of directors effective June 8, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
PTC Therapeutics reports that board member Alethia Young resigned from its board of directors effective June 8, 2026. She stated that the decision reflects the need to focus on other work commitments and was not due to any disagreement with the company.
On the same date, Young entered into a Consulting Agreement under which she will continue as an advisor to PTC Therapeutics through June 8, 2027. For these advisory services, she will receive a monthly consulting fee of $4,166.67, as detailed in Exhibit 10.1 to the report.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, or exhibit attachments filed with this report.
Key Figures
Monthly consulting fee: $4,166.67
Consulting term: June 8, 2026 – June 8, 2027
Resignation effective date: June 8, 2026
+1 more
4 metrics
Monthly consulting fee
$4,166.67
Consulting Agreement compensation for Alethia Young
Consulting term
June 8, 2026 – June 8, 2027
Duration of Alethia Young’s advisory role
Resignation effective date
June 8, 2026
Alethia Young’s resignation from the board
Exhibit 10.1
Consulting Services Agreement
Agreement between PTC Therapeutics and Alethia Young
Key Terms
board of directors, Consulting Agreement, Nasdaq Global Select Market, Emerging growth company
4 terms
board of directors financial
"Alethia Young, a member of the board of directors (the “Board”) of PTC Therapeutics, Inc."
The Board of Directors is a group of people chosen by a company's owners to help make big decisions and oversee how the company is run. They act like a team of advisors or managers, making sure the company stays on track and meets its goals. Their choices can influence the company's success and how it grows.
Consulting Agreement financial
"The Company and Ms. Young entered into a consulting agreement effective as of June 8, 2026 (the “Consulting Agreement”)"
Nasdaq Global Select Market financial
"Common Stock, $0.001 par value per share ... PTCT ... Nasdaq Global Select Market"
A Nasdaq Global Select Market listing is the highest tier of stocks on the Nasdaq exchange, reserved for companies that meet the strictest financial, reporting and governance standards. For investors, it acts like a premium quality label—signaling larger, more transparent and better-governed companies that tend to offer greater liquidity and lower perceived risk compared with lower-tier listings, making it easier to buy, sell and evaluate shares.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What board change did PTC Therapeutics (PTCT) disclose in this 8-K?
PTC Therapeutics disclosed that board member Alethia Young resigned from its board effective June 8, 2026. The company states her decision was based on other work commitments and was not related to any disagreement with PTC Therapeutics.
Did Alethia Young have any disagreement with PTC Therapeutics (PTCT) when resigning?
According to the filing, Alethia Young informed PTC Therapeutics that her resignation was not due to any disagreement with the company. She cited the need to focus on her other work activities as the reason for stepping down.
Is Alethia Young continuing in any role with PTC Therapeutics (PTCT) after resigning?
Yes. PTC Therapeutics entered into a Consulting Agreement with Alethia Young effective June 8, 2026. Under this agreement, she will remain as an advisor to the company through June 8, 2027, providing ongoing consulting services.
What compensation will Alethia Young receive as a consultant to PTC Therapeutics (PTCT)?
Under the Consulting Agreement, Alethia Young will receive a monthly consulting fee of $4,166.67. This fee compensates her for advisory services to PTC Therapeutics during the term of the agreement, which runs through June 8, 2027.
Where can investors find the full details of Alethia Young’s consulting agreement with PTC Therapeutics (PTCT)?
Full details of Alethia Young’s Consulting Services Agreement are provided in Exhibit 10.1 to the report. The 8-K states that its brief description is qualified in its entirety by reference to the complete agreement text.
What exchange lists PTC Therapeutics (PTCT) common stock?
PTC Therapeutics’ common stock, with a par value of $0.001 per share, is listed on the Nasdaq Global Select Market under the trading symbol PTCT. This listing information is confirmed in the securities section of the report.
AI-generated analysis. How Rhea-AI works. Not financial advice.
